http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-037527-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_16e8ad9bbae4a80bddae7f6642417324
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-650952
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65846
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07G5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6584
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6539
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-02
filingDate 2002-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40cebf88b1debd5da4088de6aa6f9dec
publicationDate 2004-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AR-037527-A1
titleOfInvention A PROCESS TO PREPARE AN ALCALOID REACTION PRODUCT THAT CAN BE CONVERTED IN A WATER SOLUBLE FORM, A REACTION PRODUCT OBTAINED WITH SUCH PROCESS, A MIXTURE OF THESE REACTION PRODUCTS, AND THE USE OF THE SAME IN QUALITY OF PHARMACOS
abstract A process for preparing an alkaloid reaction product that can be converted into a water soluble form, comprising the steps of: a) preparing a reaction product by reacting at least one alkaloid with a phosphorus derivative containing at least one aziridine -N group (CH2CH2) according to the general formula (1), in an organic solution at elevated temperature, in particular at the boiling temperature of the solvent, and b) washing the reaction product obtained in step a); characterized in that said reaction product is washed with water. The reaction products obtained are suitable as drugs. This process promotes the conversion of alkaloids into a water-soluble form. In particular, it allows to convert, in addition to the selected alkaloids, the total alkaloids of Chelidonium majus L and then obtain a low toxicity pharmaceutical preparation with such a wide spectrum of action. as possible. Also described are the reaction products obtained with said process, a mixture of these reaction products, and the use of said reaction products as drugs intended for the prophylaxis or treatment of diseases or organic dysfunctions selected from the group formed for cancer, immune diseases and metabolic diseases, in particular, osteoporosis, allergies, skin tumors, viral infections, rheumatic diseases, scars, postoperative lesions, epilepsy and multiple sclerosis.
priorityDate 2001-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393622
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635

Total number of triples: 52.